EP Patent
EP3710425A1 — Solid state forms of elafibranor
Assigned to Teva Pharmaceuticals International GmbH · Expires 2020-09-23 · 6y expired
What this patent protects
Disclosed are solid state forms of Elafibranor and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.
USPTO Abstract
Disclosed are solid state forms of Elafibranor and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.
Drugs covered by this patent
- Iqirvo (ELAFIBRANOR) · Ipsen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.